drugset / Trial / NCT00950989
Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate
RandomizedParallel-groupDouble-blindTreatment
Summary
Study in participants with RA who have an inadequate response to methotrexate.
Timeline
- Start
- 2009-12-30
- Primary completion
- 2011-02-11
- Completion
- 2011-02-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brodalumab | Monoclonal antibody | 70 mg | Subcutaneous |
| Subject | Brodalumab | Monoclonal antibody | 140 mg | Subcutaneous |
| Subject | Brodalumab | Monoclonal antibody | 210 mg | Subcutaneous |
| Background | Methotrexate | Small molecule | — | — |